In vivo serotonin 5-HT(2A) receptor occupancy and quetiapine.
Jones
H M
HM
Travis
M J
MJ
Mulligan
R
R
Visvikis
D
D
Gacinovic
S
S
Ell
P J
PJ
Kerwin
R W
RW
Pilowsky
L S
LS
D000328:Adult; D014150:Antipsychotic Agents / Q000493:pharmacokinetics / Q000494:pharmacology* / Q000627:therapeutic use; D002540:Cerebral Cortex / Q000187:drug effects / Q000378:metabolism; D003987:Dibenzothiazepines / Q000493:pharmacokinetics / Q000494:pharmacology* / Q000627:therapeutic use; D006801:Humans; D007457:Iodine Radioisotopes; D008297:Male; D010880:Piperidines; D000069348:Quetiapine Fumarate; D044402:Receptor, Serotonin, 5-HT2A; D011985:Receptors, Serotonin / Q000187:drug effects* / Q000378:metabolism; D012559:Schizophrenia / Q000188:drug therapy / Q000378:metabolism; D015899:Tomography, Emission-Computed, Single-Photon
D014150:Antipsychotic Agents; D003987:Dibenzothiazepines; D007457:Iodine Radioisotopes; D010880:Piperidines; C105020:R 91150; D044402:Receptor, Serotonin, 5-HT2A; D011985:Receptors, Serotonin; D000069348:Quetiapine Fumarate